Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Isabel Bover et al.|The Lancet Oncology|2012Cited by 5.5k
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusGiuseppe Curigliano, Uwe G. Liebert, Susana Banerjee et al.|Annals of Oncology|2020Cited by 313
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical OncologyPilar Garrido, Fernando López‐Ríos|Clinical & Translational Oncology|2019Cited by 104
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAlona Zer, Natasha B. Leighl, Myung‐Ju Ahn et al.|Annals of Oncology|2025Cited by 74
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancerDaniel Morgensztern, Pilar Garrido, Nina Karaseva et al.|Lung Cancer|2019Cited by 24